Moteur de recherche d’entreprises européennes
Financement de l’UE (3 926 573 €) : L’apprentissage automatique avancé au service de la découverte de médicaments innovants Hor 03/09/2020 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
L’apprentissage automatique avancé au service de la découverte de médicaments innovants
"The dramatic increase in using of Artificial Intelligence (AI) and machine learning methods in different fields of science becomes an essential asset in the development of the chemical industry, including pharmaceutical, agro biotech, and other chemical companies. However, the application of AI in these fields is not straightforward and requires excellent knowledge of chemistry. Thus, there is a strong need to train and prepare a new generation of scientists who have skills both in machine learning and in chemistry and can advance medicinal chemistry, which is the prime goal of the AIDD proposal. Research WPs include sixteen topics selected to cover the key innovative directions in machine learning in chemistry. Fellows employed will be supervised by academics who have excellent complementary expertise and contributed some of the fundamental AI algorithms which are used billions of times per day in the world, and leading EU Pharma companies who are in charge of new medicine and public health. All developed methods can be used individually but will also contribute to an integrated ""One Chemistry"" model that can predict outcomes ranging from different properties to molecule generation and synthesis. Training on various modalities allows the model to understand how to intertwine chemistry and biology to develop a new drug making its design robust and explainable. All partners agreed to make their software open source. It will boost the field and will provide the broadest possible dissemination of the results both to the academy and industry, including SMEs. The network will offer comprehensive, structured training through a well-elaborated Curriculum, online courses, and six Schools. The IP policy and commercial exploitation of the project results have the highest priority supported by intellectual property asset management organizations. Comprehensive public engagement activities will complement the dissemination of results to the scientific community."
| Aalto Korkeakoulusaatio sr | 280 806 € |
| Astrazeneca AB | 790 492 € |
| Bayer AG | 126 394 € |
| Enamine LLC,Research And Production Enterprise | 0,00 € |
| Freie Universitaet Berlin | 66 006 € |
| Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit UND Umwelt GmbH | 390 207 € |
| Janssen Pharmaceutica N.V. | 640 800 € |
| Johannes Gutenberg-Universitat Mainz | 91 285 € |
| Katholieke Universiteit Leuven | 128 160 € |
| Pfizer Pharma GmbH | 379 183 € |
| Scuola Universitaria Professionale Della Svizzera Italiana | 140 638 € |
| Technische Universitat Dortmund | 35 110 € |
| Universidad Pompeu Fabra | 125 452 € |
| Universitat Linz | 264 207 € |
| Universitat Wien | 132 104 € |
| Universite Du Luxembourg | 202 920 € |
| Universiteit Leiden | 132 810 € |
https://cordis.europa.eu/project/id/956832
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.